WHO ICTRP trial
Study for the effects of semaglutide on glycemic control and quality of life in…
JPRN-UMIN000042369 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000042369 |
|---|---|
| Public title | Study for the effects of semaglutide on glycemic control and quality of life in patients with type 2 diabetes |
| Scientific title | Comparison of the effect on glycemic control and quality of life between semaglutide and, liraglutide or dulaglutide in patients with type 2 diabetes -prospective randomized controlled trial- (SWITCH-SEMA 1) - Semaglutide study (SWITCH-SEMA 1) |
| Primary sponsor | Hokkaido University Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | Japan |
| Conditions | Type 2 diabetes |
| Interventions | Switching from liraglutide (0.9-1.8mg/day) to once-weekly semaglutide (0.25-1.0mg/week) Continue liraglutide (0.9-1.8mg/day) Switching from dulaglutide (0.75mg/week) to once-weekly semaglutide (0.25-1.0mg/week) Continue dulaglutide… |
| Registration date | Jun 11, 2020 |
| Target size | 100 |
| Secondary IDs | jRCT1011200008;018-005 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: